Ignite Creation Date:
2024-05-06 @ 2:56 PM
Last Modification Date:
2024-10-26 @ 1:40 PM
Study NCT ID:
NCT04479241
Status:
COMPLETED
Last Update Posted:
2023-09-28
First Post:
2020-07-16
Brief Title:
LUMINOS-101 Lerapolturev PVSRIPO and Pembrolizumab in Patients with Recurrent Glioblastoma
Sponsor:
Istari Oncology Inc
Organization:
Istari Oncology Inc
Study Overview
Official Title:
A Phase 2 Open-label Single-arm Study Evaluating the Efficacy Safety and Tolerability of Lerapolturev PVSRIPO and the Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of Patients with Recurrent Glioblastoma
Status:
COMPLETED
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This Phase 2 single arm trial in patients with rGBM will characterize the efficacy safety tolerability and initial efficacy of lerapolturev intratumoral infusion followed by intravenous pembrolizumab 14 to 28 days later and every 3 weeks thereafter
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None